


# New Drugs & Technologies

## 5-Year Scan

Kiran Yemul, MHS  
Oncology, Sg2

January 24, 2020



An orange line starts from a dot on the right side of the slide, extends horizontally to the left, then turns 90 degrees down to a second dot, and then continues vertically down to a third dot. The word "Agenda" is positioned to the right of the second dot.

## Agenda

CAR T-Cell Therapy

Artificial Intelligence

Adaptive Radiation Therapy

What's Next?

# Successful Innovation Is...

Fully integrated into  
your organizational  
**strategy**



Structured to match  
your organizational  
**culture**

Answers the  
**critical questions**

# Measure Return on New Technologies Across Four Strategic Levers





## Agenda

### **CAR T-Cell Therapy**

Artificial Intelligence

Adaptive Radiation Therapy

What's Next?

# FDA Approved CAR T-cell Therapies Are Here, Additional Indications to Come

## LEUKAPHERESIS

Collect patient's white blood cells



## MANUFACTURING PROCESS

Isolate and activate T cells



Engineer T cells with CAR gene



Grow and expand number of T cells



## INFUSION

Infuse same patient with engineered T cells



## 5-Year Impact

- Expanded availability, patient volumes
- Replace some BMT volume

ALL = acute lymphoblastic leukemia; NHL = non-Hodgkin lymphomas; MM = multiple myeloma; BMT = bone marrow transplant.

Source: Sg2 Impact of Change Forecast, 2019; figure: Dana Farber Cancer Institute.

Confidential and Proprietary © 2019 Sg2



# Reimbursement for CAR T Is an Area of Ongoing Development...and Concern

## ● August 2019, CMS final reimbursement and coverage determination released

### **Inpatient:**

- NTAP increased from 50% to 65%
- Institutions still on the hook for at least \$130,550 per case!
- No new MS-DRG for CAR T

### **Outpatient:**

- ASP +6% = \$395K for Yescarta and \$503K for Kymriah

## **Commercial coverage usually via SCAs (with varying efficiency)**

- Novartis: Money-back guarantee
- Spark Therapeutics: Rebates, bill payer directly, installment payments

ASP = average sales price. Sources: CMS, 2019; Rosenberg J. CMS Proposes Increased Reimbursement for CAR T-Cell Therapy. AJMC; April 24, 2019. CMS Proposes coverage with evidence development for chimeric antigen receptor (CAR) T-cell Therapy. CMS.gov; February 15, 2019. Delay in Final Chimeric Antigen Receptor (CAR) T-cell therapy National Coverage Determination; CMS.gov; May 17, 2019. Pasternack A. This pioneering \$475,000 cancer drug comes with a money-back guarantee. FastCompany.com. August 31, 2017; Sg2 Analysis, 2019.

## CASE STUDY

# Different Models for CAR T-Cell Delivery, All Require Multidisciplinary Care

### Integrated

#### Memorial Sloan Kettering Cancer Center

- Consult service
- Leverage existing infrastructure for regulatory, cellular processing, clinical care delivery
- Benefits from optimized workflows e.g. data and quality management
- Centralized intake for BMT and commercial and investigational CAR T
- Avoid program redundancies
- Challenge: post-infusion management

### Standalone

#### Seattle Cancer Care Alliance

- Cellular Immunotherapy Service
- Outpatient-based clinical care
- Dedicated clinical care team with enhanced expertise in the unique CAR T-cell toxicities
- Offer expanded outpatient hours
- IP care coordinated with BMT service
- Accommodates increasing patient volumes and eases the administrative burden on individual disease teams
- Challenges: cost, referral management

MDC = multidisciplinary clinic.

Sources: Taylor L, et al. 2019 *Clin J Oncol Nurs* Building a Program: Implications for Infrastructure, Nursing Education, and Training for CAR T-Cell Therapy, 23(2), 20-26.


Confidential and Proprietary © 2019 Sg2



# CAR T is Blazing the Trail for Other Innovative Immunotherapies

## Bi-specific T-cell Engagers (BiTEs)

- Antibodies that bind T-cells to tumor cells
- Off-the-shelf treatment
- 2014: FDA approval for blinatumomab (Blincyto, Amgen) for ALL
- Clinical trials ongoing for expanded indications, solid tumor applications (prostate, CRC, melanoma)



## Key Takeaways

- Roadblocks to solid tumor CAR T are non-trivial
- Notable advantages of immunotherapies over traditional chemo and radiation
- Implementation challenges grease the wheels for other immunotherapies



## Agenda


CAR T-Cell Therapy

**Artificial Intelligence**

Adaptive Radiation Therapy

What's Next?

# FDA APPROVALS FOR ARTIFICIAL INTELLIGENCE-BASED ALGORITHMS IN MEDICINE




# CASE STUDY

## AI Is Leveraged Today to Improve Operations

### JOHNS HOPKINS HOSPITAL, BALTIMORE, MD

Partnered with GE Healthcare to develop an AI-driven command center



**Sources:** Johns Hopkins Medicine. The Johns Hopkins Hospital launches capacity command center to enhance hospital operations [news release]. October 26, 2016; Johns Hopkins Medicine. Command center to improve patient flow. *Insight*. March 2016; Slabodkin G. Johns Hopkins Hospital command center is first of its kind. *HealthData Management*. January 24, 2017.



## ABRAMSON CANCER CENTER, UNIVERSITY OF PENNSYLVANIA

### Situation

- Providers challenged to initiate end of life care conversations

### Solution

- Developed AI to predict the risk of 6-month mortality risk among cancer patients
- Integrated EHR notifications encouraged physicians to initiate care planning conversations



### IMPACT

- Palliative care consultation increased by **74 percent**
- Anticipated savings for health systems via reduced spending on noncurative chemotherapy and other maintenance therapies

Source: Parikh RB, et al. *JAMA Oncology*. 25 Oct 2019; Machine Learning Approaches to Predict 6-Month Mortality Among Patients With Cancer, 2(10):e1915997.

# Artificial Intelligence Is Making A Move Into Radiation Therapy Treatment Planning

- **AI Works Alongside Doctors to Improve Radiation Treatment Planning Process**
  - Quickly differentiate tumor versus healthy tissue for every image
  - Easily performs OAR analysis
  - Rely on database of previous treatment plans
  - Develop machine learning algorithms
  - Workflow efficiency substantially improves



## RaySearch

RayStation/UHN

- Uses machine learning and image processing from thousands of previous plans
- Integrated into existing RayStation platform

## Microsoft

InnerEye/Addenbrooke

- Assistive AI to treat cancer and monitor progress
- Goal is to have AI do 95% of work and shorten time from hours to minutes

## Google


DeepMind Health/UCLH

- Partnership to develop new treatment planning tool
- 700 former head/neck patients
- 75% reduction in treatment planning time to 1hr

OAR = organs at risk; UCLH = University College London Hospital; UHN = University Health Network  
Sources: University College London Hospital; RaySearch Laboratories; Project InnerEye, Microsoft; Google DeepMind Health, LLC.



# 7 Steps to Prepare for Artificial Intelligence Today



**Focus on the conversation and the technology disappears.**

Source: Sg2 Analysis, 2017.

Confidential and Proprietary © 2019 Sg2

## Agenda

CAR T-Cell Therapy  
Artificial Intelligence

**Adaptive Radiation Therapy**

What's Next?

# Adaptive Radiation Therapy Allows for More Precise Treatment Delivery

Adapt treatment in response to changes in size, position, and shape of tumors and organs at risk



## Adaptive Radiation Therapy (ART)

- Image guidance
- Treatment adaptation
  - Patient repositioning
  - Treatment re-planning/re-optimization
- Dose verification
- Useful in difficult to treat regions - head & neck, pancreas, prostate

## 5-Year Impact

- Expanded availability of IGRT and ART, new market entrants
- AI meets ART

Sources: Lamb J et al. Cureus. Online Adaptive Radiation Therapy: Implementation of a New Process of Care, 2017 Aug; 9(8): e1618; Li T, Towards the Clinical Implementation of Online Adaptive Radiation Therapy for Prostate Cancer, 2013; Zagoudis J, Imaging Technology News, 29 May 2019, Advances in Radiation Therapy Treatment Systems.; Sg2 Analysis, 2019.

# MR-Guided Radiotherapy Has Become a Reality

- Concept announced in 2002; first system installed at UMC Utrecht in 2014
- Real-time, continuous MR imaging during treatment
- Adaptive, on-bed radiation therapy planning
- MR-guided radiotherapy is particularly beneficial for soft tissue tumors, tumors near critical structures, and accurate gating and tumor movement.




Image courtesy of ViewRay.

## ViewRay—MRIdian(LINAC)

- 6 MV linear accelerator, 0.35T MR
- FDA cleared (2012, 2017)
- Installed at BJH, UCLA, UWisc
  - BJH: breast (18%), lung (14%), colorectal (13%), bladder (12%), prostate (5%)

## Elekta/Philips—Unity

- 6 MV linear accelerator and 1.5T MR
- 7 member Atlantic Research Consortium includes 2 US facilities: MD Anderson, Froedtert/MCOW
- Early projections
  - 75 orders expected by EOY 2019; costs \$8 - \$10M

BJH = Barnes-Jewish Hospital; MCOW = Medical College of Wisconsin; MR = magnetic resonance; UCLA = University of California Los Angeles; UMC = University Medical Center; UW = University of Wisconsin



# Turning Cancer Against Itself With Biology-guided Radiation Therapy

## • **Reflexion Medical; Biology-guided Radiotherapy (BgRT)**

- LINAC with PET emission detectors for IMRT and stereotactic radiation delivery
- Delivers beamlet of radiation in response to each tracer emission along the line of response (LOR)
- Dynamic real-time tracking; same session treatment for multiple mets
- Reduced treatment margins and lower radiation dose to healthy tissue

***“Tumors continuously signal their location during treatment”***



Linac = linear accelerator; mets = metastatic cancer.

Sources: Reflexion Medical website <https://www.reflexion.com/>; ASTRO 2018.



## Agenda

CAR T-Cell Therapy

Artificial Intelligence

Adaptive Radiation Therapy

**What's Next?**



## Extras: What Else to Watch for in 2020 and Beyond

1. Expanding indications for liquid biopsy
2. New applications for cancer vaccines
3. Clinical trial data on proton therapy
4. Direct-to-consumer genetic risk assessment
5. Direct-to-consumer cancer screening
6. New PET radiotracers and better availability
7. *In silico* cancer drug trials
8. At-home lab marker measurement
9. New wearable therapeutics (e.g. brain cancer, pain management)



## Wrap Up: What's Next?

- As CAR T-cell demand and indications will grow, look for future developments in reimbursement landscape
- Position your organization on the AI learning curve by understanding how AI can support your patients and care teams
- Empower providers with “precision” radiation oncology tools e.g. adaptive radiation therapy technologies
- Prepare for direct-to-consumer cancer offerings that will disrupt traditional service offerings

Questions



Sg2, a Vizient company, is the health care industry's premier authority on health care trends, insights and market analytics.

Our analytics and expertise help hospitals and health systems achieve sustainable growth and ensure ongoing market relevance through the development of an effective System of CARE.



health care intelligence

**Sg2.com**

847.779.5300

# Your 100-Day Plan in 7 Steps

1. Rank in priority order your patient interactions by how critical they are to your current revenue and future growth.
2. Pick the top 3 to 5 interactions and work with your service line and product teams to streamline patient engagement with your most important services. This process will help identify areas where AI can improve future interactions.
3. Identify what information and insights you lack that would help you improve the patient experience. Design your AI tools to help access and use and to provide key insights to you and your patients.
4. Develop AI personas that fit your brand and communicate your brand voice.
5. Begin adding sophistication to your digital interactions. Consider piloting AI in roles like content curator (for personalization) or interaction advisor (for intelligent automation). These new roles should accompany the patient along their various journeys.
6. Identify communication channels and platforms for integrating conversational experiences with your brand. Consider internal as well as external interactions.
7. Gather and review existing key performance indicators (KPIs) for patient success. Ensure these KPIs account for the benefits of simplified interactions.